Back to Search
Start Over
Higher small pulmonary artery and vein volume on computed tomography is associated with mortality in current and former smokers.
- Source :
-
EBioMedicine [EBioMedicine] 2024 Oct; Vol. 108, pp. 105366. Date of Electronic Publication: 2024 Sep 30. - Publication Year :
- 2024
-
Abstract
- Background: In chronic obstructive pulmonary disease (COPD), vascular alterations have been shown to contribute to hypoxia and pulmonary hypertension, but the independent contribution of small vessel abnormalities to mortality remains unclear.<br />Methods: We quantified artery and vein dimensions on computed tomography (CT) down to 0.2 mm. Small vessel volumes (<1 mmá´“) were normalized by body surface area. In 7903 current and former smokers of the COPDGene study (53.2% male) the independent contribution of small artery and small vein volume to all-cause mortality was tested in multivariable Cox models. Additionally, we calculated the 95 <superscript>th</superscript> percentile of small arteries and veins in 374 never smokers to create two groups: normal and high small artery or vein volume. We describe clinical, physiological and imaging characteristics of subjects with a high small artery and high small vein volume.<br />Findings: Both high small artery and high small vein volumes were independently associated with mortality with an adjusted hazard ratio of 1.07 [1.01, 1.14] and 1.34 [1.21, 1.49] per mL/m <superscript>2</superscript> increase, respectively. In COPDGene, 447 (5.7%) had high small artery volume and 519 (9.1%) subjects had high small vein volume and both had more emphysema, more air trapping and more severe coronary calcium.<br />Interpretation: In smokers, abnormally high volumes in small arteries and veins are both relevant for mortality, which urges investigations into the aetiology of small pulmonary vessels and cardiac function in smokers.<br />Funding: Award Number U01-HL089897 and U01-HL089856 from the NHLBI. COPD Foundation with contributions from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion.<br />Competing Interests: Declaration of interests AK, EA, TV, EP: no conflicts relevant to this manuscript. DL and SH: the department of radiology of National Jewish Health received grant support from the NHLBI. PdJ: The Department of Radiology from the UMC Utrecht receives research support from Philips Healthcare. JPC: employee and shareholder of Thirona. LGE, HT: employee of Thirona.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Pulmonary Disease, Chronic Obstructive mortality
Pulmonary Disease, Chronic Obstructive diagnostic imaging
Smoking adverse effects
Pulmonary Veins diagnostic imaging
Pulmonary Veins pathology
Proportional Hazards Models
Pulmonary Artery diagnostic imaging
Pulmonary Artery pathology
Tomography, X-Ray Computed methods
Smokers
Subjects
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 108
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 39353280
- Full Text :
- https://doi.org/10.1016/j.ebiom.2024.105366